Choice of Preventive Treatment for Isoniazid-resistant Tuberculous Infection. Use of Decision Analysis and the Delphi Technique
Overview
Authors
Affiliations
Proper care of persons infected with isoniazid-resistant tubercle bacilli is controversial because there are few data on the risks and benefits of the preventive treatment alternatives. Decision analysis was used to facilitate a comparison of outcomes using different strategies and the Delphi technique to obtain estimates of relevant probabilities. For all probabilities of isoniazid resistance, the observation and no-drug alternative is unsatisfactory because it sould result in a twofold to sevenfold greater number of tuberculosis cases than any of the drug regimens. With a low probability of isoniazid resistance, isoniazid is the preventive treatment of least cost and proved efficacy. As the probability of isoniazid resistance increases, more cases are prevented by rifampin-containing regimens, but at added cost. These findings can be used to formulate appropriate preventive treatment recommendations.
Isoniazid-resistant tuberculosis: a cause for concern?.
Stagg H, Lipman M, McHugh T, Jenkins H Int J Tuberc Lung Dis. 2017; 21(2):129-139.
PMID: 28234075 PMC: 5479083. DOI: 10.5588/ijtld.16.0716.
Landrigan P, Schechter C, Lipton J, Fahs M, Schwartz J Environ Health Perspect. 2002; 110(7):721-8.
PMID: 12117650 PMC: 1240919. DOI: 10.1289/ehp.02110721.
Debrix I, Flahault A, Becker A, Schwartz L, KANFER A, Milleron B Br J Clin Pharmacol. 1999; 48(4):616-22.
PMID: 10583034 PMC: 2014380. DOI: 10.1046/j.1365-2125.1999.00048.x.
Treatment and prevention of multidrug-resistant tuberculosis.
Bastian I, Colebunders R Drugs. 1999; 58(4):633-61.
PMID: 10551435 DOI: 10.2165/00003495-199958040-00005.
Menzies D, Tannenbaum T, Fitzgerald J CMAJ. 1999; 161(6):717-24.
PMID: 10513279 PMC: 1230622.